Medical
NEW
VT3989 Achieves 32% Response Rate in Mesothelioma: First Hippo Pathway Drug Nears FDA Approval
David Foster
February 15, 2026
VT3989 shows 32% response rate and 86% disease control in refractory mesothelioma. Learn about this first-in-class TEAD inhibitor's path to FDA approval and clinical trial access.
15 min read 8 FAQs
Read